Elevated intraocular pressure (IOP) is a well-documented glaucoma risk factor.1,2 Several lines of evidence point to the lamina cribrosa of the optic nerve head (ONH) as the initial site of axonal injury in this disease.3–5 Clinically, glaucoma is characterized by optic disc cupping, neuroretinal rim thinning, and progressive visual field loss. Glaucomatous human eyes demonstrate optic nerve axon and retinal ganglion cell loss accompanied by ONH remodeling and glial scarring.6 Many of these pathophysiological changes are replicated in animal models of glaucoma in which IOP is either experimentally or genetically elevated.4,6–9 Within the normal ONH, astrocytes are arranged into columns. Their processes are oriented perpendicular to retinal ganglion cell axons, separating them into bundles. Astrocytes are the most abundant glial cell type in the ONH, along with microglia. In the posterior ONH, oligodendroglial are increasingly prevalent as axons become myelinated. Both in human glaucoma and in animal glaucoma models with elevated IOP, astrocytes lose their typical arrangement and, along with microglia, alter their morphology.10–17

In addition to these morphologic changes, our previous studies have shown an upregulation of many cell proliferation-associated genes in glaucoma model ONHs.18,19 To more fully understand the details of this observation, we previously quantified glaucoma model ONH DNA content and found that this increased between 117% (early injury) and 184% (advanced injury) compared to controls.18,19 Furthermore, we showed by three-dimensional reconstructions that the mean ONH volume increased by 40% in early injury glaucoma model nerves.20 These studies provide support for increased cellularity within the glaucomatous ONH but have yet to document cell proliferation or determine which ONH cells are involved in this process.

In addition to these proliferation findings, we found that minimally injured ONHs showed an upregulation of several interleukin-6 type cytokines (If6, Lif, Clcf1) and Sox3, the feedback inhibitor of Stat3 phosphorylation (pStat3), suggesting an early activation of the Janus kinase and signal transducer and activator of transcription (Jak-Stat) pathway.18,19 Jak-Stat pathway activation has been shown to regulate glial cell proliferation, as well as astrocytic differentiation, and this pathway may play an important role in the glial responses we have observed in pressure-induced injury.17,18,21–25

The purpose of this study is to answer hypotheses generated by our previous microarray work and identify, in chronic glaucoma model ONHs with early and advanced injury, the presence of proliferating (mitotic) cells and Jak-Stat pathway activation and determine which cells are involved.

### Purpose

We previously reported increased expression of cell proliferation and Jak-Stat pathway–related genes in chronic experimental glaucoma model optic nerve heads (ONH) with early, mild injury. Here, we confirm these observations by localizing, identifying, and quantifying ONH cellular proliferation and Jak-Stat pathway activation in this model.

### Methods

Chronic intraocular pressure (IOP) elevation was achieved via outflow pathway sclerosis. After 5 weeks, ONH longitudinal sections were immunolabeled with proliferation and cell-type markers to determine nuclear densities in the anterior (unmyelinated) and transition (partially myelinated) ONH. Nuclear pStat3 labeling was used to detect Jak-Stat pathway activation. Nuclear density differences between control ONH (uninjected) and ONH with either early or advanced injury (determined by optic nerve injury grading) were identified by ANOVA.

### Results

Advanced injury ONH had twice the nuclear density ($P < 0.0001$) of controls and significantly greater astrocyte density in anterior ($P = 0.0001$) and transition ($P = 0.006$) ONH regions. An increased optic nerve injury grade positively correlated with increased microglia/macrophage density in anterior and transition ONH ($P < 0.0001$, both). Oligodendroglial density was unaffected. In glaucoma model ONH, 80% of anterior and 66% of transition region proliferating cells were astrocytes. Nuclear pStat3 labeling significantly increased in early injury anterior ONH, and 95% colocalized with astrocytes.

### Conclusions

Astrocytes account for the majority of proliferating cells, contributing to a doubled nuclear density in advanced injury ONH. Jak-Stat pathway activation is apparent in the early injury glaucoma model ONH. These data confirm dramatic astrocyte cell proliferation and early Jak-Stat pathway activation in ONH injured by elevated IOP.

Keywords: glaucoma, animal models, optic nerve, cell proliferation

---

**Early Optic Nerve Head Glial Proliferation and Jak-Stat Pathway Activation in Chronic Experimental Glaucoma**

Diana C. Lozano, Tiffany E. Choe, William O. Cepurna, John C. Morrison, and Elaine C. Johnson

Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States

Correspondence: Diana C. Lozano, Casey Eye Institute, Oregon Health & Science University, 3375 SW Terwiliger Boulevard, Portland, OR 97239-4197, USA; lozano@ohsu.edu.

Submitted: September 11, 2018

Accepted: January 25, 2019

Citation: Lozano DC, Choe TE, Cepurna WO, Morrison JC, Johnson EC. Early optic nerve head glial proliferation and Jak-Stat pathway activation in chronic experimental glaucoma. Invest Ophthalmol Vis Sci. 2019;60:921–932. https://doi.org/10.1167/iovs.18-25700

**Purpose.** We previously reported increased expression of cell proliferation and Jak-Stat pathway–related genes in chronic experimental glaucoma model optic nerve heads (ONH) with early, mild injury. Here, we confirm these observations by localizing, identifying, and quantifying ONH cellular proliferation and Jak-Stat pathway activation in this model.

**Methods.** Chronic intraocular pressure (IOP) elevation was achieved via outflow pathway sclerosis. After 5 weeks, ONH longitudinal sections were immunolabeled with proliferation and cell-type markers to determine nuclear densities in the anterior (unmyelinated) and transition (partially myelinated) ONH. Nuclear pStat3 labeling was used to detect Jak-Stat pathway activation. Nuclear density differences between control ONH (uninjected) and ONH with either early or advanced injury (determined by optic nerve injury grading) were identified by ANOVA.

**Results.** Advanced injury ONH had twice the nuclear density ($P < 0.0001$) of controls and significantly greater astrocyte density in anterior ($P = 0.0001$) and transition ($P = 0.006$) ONH regions. An increased optic nerve injury grade positively correlated with increased microglia/macrophage density in anterior and transition ONH ($P < 0.0001$, both). Oligodendroglial density was unaffected. In glaucoma model ONH, 80% of anterior and 66% of transition region proliferating cells were astrocytes. Nuclear pStat3 labeling significantly increased in early injury anterior ONH, and 95% colocalized with astrocytes.

**Conclusions.** Astrocytes account for the majority of proliferating cells, contributing to a doubled nuclear density in advanced injury ONH. Jak-Stat pathway activation is apparent in the early injury glaucoma model ONH. These data confirm dramatic astrocyte cell proliferation and early Jak-Stat pathway activation in ONH injured by elevated IOP.

Keywords: glaucoma, animal models, optic nerve, cell proliferation
Animal experiments were performed in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. IOP was unilaterally elevated in 8-month-old, male retired breeder Brown Norway rats (N = 37) by a single episcleral vein injection of hypertonic saline. IOP was measured with a rebound tonometer (TonoLab; Colonial Medical Supply, Framingham, MA, USA) in unanesthetized rats as previously described. Animals were kept in constant dim light for the duration of the experiment, and IOP measurements were acquired prior to episcleral vein injection and at least three times a week for the duration of the experiment (5 weeks). IOP for each time point was calculated as the mean of 10 individual TonoLab readings. Mean IOP was then determined as the area under the curve of IOP (less the control fellow eye value) for the duration of the experiment, and IOP measurements were randomized into batches (each batch contained control and experimental globes), embedded in paraffin, and longitudinally sectioned vertically, with two sections per slide and 10 to 15 slides per globe. Slides were assigned into immunohistochemistry assay groups to include controls and globes with the full range of nerve injuries in each assay. Sections were immunolabeled with Ki67 or pStat3 and a cell type–specific antibody (Sox2, Iba1, etc.). All slides were labeled with DAPI (4’,6-diamidino-2-phenylindole). For the comparisons between anterior and transition regions, slides were selected that contained both, as illustrated in Figure 1. Not every eye was included in every analysis due to the limited number of sections per ONH and availability of appropriate sections for regional comparisons. The sample size for each analysis is provided in each table and figure.

Within each immunohistochemistry assay group, sections were deparaffinized, rehydrated in PBS, and blocked in either 5% goat (Vector Laboratories, Burlingame, CA, USA), horse (Vector Laboratories) or SEA BLOCK blocking buffer (ThermoFischer Scientific, Waltham, MA, USA) in PBS, and incubated overnight at 4°C with primary antibodies (Supplementary Table S2). For cell-type markers, primary antibodies used were goat anti-Sox2 (0.3 μg/mL; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for astrocyte nuclei; rabbit anti-Pax2 (0.5 μg/mL; Invitrogen, Carlsbad, CA, USA) for astrocyte nuclei; anti-rabbit glial fibrillary acidic protein (anti-GFAP) (0.5 μg/mL; Vector Laboratories). For glial fibrillary acidic protein (GFAP) labeling, sections were preincubated with normal rabbit serum (Dako, Carpinteria, CA, USA) and blocked in either 5% goat or 1% normal donkey serum (Jackson ImmunoResearch, West Grove, PA, USA) in PBS. For nuclei labeling, sections were immunolabeled with goat anti-Ki67 (Abcam, Cambridge, MA, USA) or rabbit anti-pStat3 (Cell Signaling Technology, Beverly, MA, USA) in PBS, and incubated for 1 h in Alexa Fluor 488 goat anti-goat IgG (Invitrogen) or Alexa Fluor 546 goat anti-rabbit IgG (Invitrogen) in PBS. Slides were incubated with 0.5 μg/mL DAPI in PBS for 10 min.

### ONH Immunohistochemistry

Globes, including the ONH, from the above animals were processed for ONH cell identification and quantitation. Globes were randomized into batches (each batch contained control and experimental globes), embedded in paraffin, and longitudinally sectioned vertically, with two sections per slide and 10 to 15 slides per globe. Slides were assigned into immunohistochemistry assay groups to include controls and globes with the full range of nerve injuries in each assay. Sections were immunolabeled with Ki67 or pStat3 and a cell type–specific antibody (Sox2, Iba1, etc.). All slides were labeled with DAPI (4’,6-diamidino-2-phenylindole). For the comparisons between anterior and transition regions, slides were selected that contained both, as illustrated in Figure 1. Not every eye was included in every analysis due to the limited number of sections per ONH and availability of appropriate sections for regional comparisons. The sample size for each analysis is provided in each table and figure.

Within each immunohistochemistry assay group, sections were deparaffinized, rehydrated in PBS, and blocked in either 5% goat (Vector Laboratories, Burlingame, CA, USA), horse (Vector Laboratories) or SEA BLOCK blocking buffer (ThermoFischer Scientific, Waltham, MA, USA) in PBS, and incubated overnight at 4°C with primary antibodies (Supplementary Table S2). For cell-type markers, primary antibodies used were goat anti-Sox2 (0.3 μg/mL; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for astrocyte nuclei; rabbit anti-Pax2 (0.5 μg/mL; Invitrogen, Carlsbad, CA, USA) for astrocyte nuclei; anti-rabbit glial fibrillary acidic protein (anti-GFAP) (0.5 μg/mL; Vector Laboratories). For glial fibrillary acidic protein (GFAP) labeling, sections were preincubated with normal rabbit serum (Dako, Carpinteria, CA, USA) and blocked in either 5% goat or 1% normal donkey serum (Jackson ImmunoResearch, West Grove, PA, USA) in PBS. For nuclei labeling, sections were immunolabeled with goat anti-Ki67 (Abcam, Cambridge, MA, USA) or rabbit anti-pStat3 (Cell Signaling Technology, Beverly, MA, USA) in PBS, and incubated for 1 h in Alexa Fluor 488 goat anti-goat IgG (Invitrogen) or Alexa Fluor 546 goat anti-rabbit IgG (Invitrogen) in PBS. Slides were incubated with 0.5 μg/mL DAPI in PBS for 10 min.

### METHODS

#### Chronic IOP Elevation and IOP Monitoring

All animal experiments were approved by the Oregon Health & Science University Institutional Animal Care and Use Committee and were performed in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. IOP was unilaterally elevated in 8-month-old, male retired breeder Brown Norway rats (N = 37) by a single episcleral vein injection of hypertonic saline. IOP was measured with a rebound tonometer (TonoLab; Colonial Medical Supply, Framonia, NH, USA) in unanesthetized rats as previously described. Animals were kept in constant dim light for the duration of the experiment, and IOP measurements were acquired prior to episcleral vein injection and at least three times a week for the duration of the experiment (5 weeks). IOP for each time point was calculated as the mean of 10 individual TonoLab readings. Mean IOP was then determined as the area under the curve of IOP (less the control fellow eye value) divided by the number of experimental days. Peak IOP was calculated as the maximum recorded measurement during the experimental period.

#### Optic Nerve Injury Grading

Animals were anesthetized and perfused transcardially with buffered 4% paraformaldehyde, as previously described. Retrobulbar optic nerves (~1 mm behind the globe) were postfixed in buffered 5% glutaraldehyde and 1% osmium tetroxide, embedded in Spurr’s resin, and cross-sectioned for light microscopic evaluation, as previously described. Briefly, nerve cross-sections were stained with toluidine blue and subjected to light microscopic evaluation, as previously described. Images illustrate an optic nerve cross-section from a glaucoma model eye with early injury (grade = 2.13). The red arrowheads in the zoomed image (red box) indicate three degenerating axons.
Dako, Carpinteria, CA, USA) for astrocytes; rabbit anti-Iba1 (anti-Aif1, 0.1 µg/mL, Wako Pure Chemical Industries Ltd., Richmond, VA, USA) for microglia/macrophage cells; and rabbit anti-Olig2 (1 µg/mL; Novus Biologicals, Littleton, CO, USA) for oligodendroglia nuclei. Also, mouse anti-Ki67 (usually 0.1 µg/mL, 2 µg/mL for colabeling with Iba1 only; Dako) was used to identify mitotic nuclei and mouse anti-pStat3 (Tyr705, 1:100; Cell Signaling, Danvers, MA, USA) was used to detect activation of the Jak-Stat pathway.

As has been published previously, these specific primary antibodies were used for antigen immunolocalization in eye or central nervous system tissues as noted in Supplementary Table S2. Additional labeling was performed using the avidin-biotin technique with 3,3′-diaminobenzidine (DAB) chromogen with each primary antibody at the same concentrations as noted in Supplementary Table S2. We provide supplementary images of the cornea (Supplementary Fig. S1) and retina (Supplementary Fig. S2), using DAB to illustrate the specific and expected labeling with these antibodies elsewhere in the eye.

After primary antibody incubation, sections were washed in PBS, incubated for 30 minutes at room temperature in the appropriate 0.2% 488 anti-mouse IgG (Alexa Fluor 488; Life Technologies, Grand Island, NY, USA) and 0.2% anti-rabbit or anti-goat IgG (Alexa Fluor 594; Life Technologies) in blocking solution, washed again, and each slide was then coverslipped after applying a drop of antifade mounting media (Prolong Gold; Life Technologies) containing DAPI (used to identify nuclei). A control and glaucoma model ONH slide with the substitution of isotype IgGs for the primary antibodies at equivalent protein dilution were processed along with each assay as checks for nonspecific labeling (Supplementary Figs. S1 and S2). Each processed slide contained two sections, and the ONH section with the best morphology was photographed (at 20X magnification) with a fluorescence microscope (Olympus America, Center Valley, PA, USA) equipped with a digital camera and associated software (DP71; Olympus America). During all steps of this project, care was taken to avoid batch effects and to control for background fluorescence. For example, for each immunostaining assay, sections from each experimental group and IgG controls were processed simultaneously. Prior to acquiring images, the IgG control slides were viewed to determine background fluorescence. Then, control and experimental slides were briefly viewed to determine a standard camera exposure setting for each primary antibody tested. Once a standard exposure setting was selected, all photography was done at the same time using identical magnification.

For triple labeling, DAPI and the primary antibody Ki67 were used in combination with either Sox2, Pax2, Iba1, or Olig2 to identify the proportion of proliferating cells that colabeled with each cell type within the ONH. DAPI and primary antibody pStat3 were used in combination with Sox2 or Iba1 to identify activation of the Jak-Stat pathway within either astrocytes or microglia/macrophages, respectively. Lastly, to determine the specificity of Sox2 as an ONH astrocyte nuclear label, we used Sox2 in combination with GFAP, Pax2, Iba1, or Olig2 (Supplementary Fig. S3). We found that of Sox2+-labeled nuclei, 86% colabeled with GFAP+ cells, 41% with Pax2+ nuclei, 2% with Iba1+ cells, and 22% with Olig2+ nuclei.

ONH Nuclear Identification and Quantitation

A program (Matlab R2015a and Image Processing Toolbox; The Mathworks, Inc., Natick, Massachusetts, USA) was developed to semiautomatically identify and quantitate ONH nuclei. We specifically compared and contrasted nuclear densities in the unmyelinated anterior ONH (from Bruch’s membrane [BM] to 150 µm posterior to BM) and the partially myelinated transition ONH (from 250 to 400 µm posterior to BM; Fig. 1B).

This program was developed to colocalize DAPI+ nuclear marker with labeling by each cell type antibody. This was accomplished by manually cropping the image to include only the desired ONH region. Image contrast for each color channel was independently and automatically adjusted by removing background noise, correcting for uneven background illumination, and improving image contrast. Each color channel was then thresholded at a standardized level. Given that the camera exposure settings during image acquisition were uniform, a standardized threshold level could be set for each tested primary antibody. In the event that the program yielded too many false positives (e.g., identification of nonnuclear structures), the user could manually adjust the threshold level until all appropriate nuclei were identified.

Nuclei centers were then identified using Matlab built-in functions, and the x- and y-coordinates for each identified nucleus were plotted back onto the ONH images to visually confirm that all appropriate nuclei were identified, allowing the user to add any nuclei missed by the program. These steps were repeated for all color channels independently, and colocalization was determined by multiplying the thresholded images together, such that a pixel value of one was plotted in the location of colabeled nuclei and zeros everywhere else. For example, nuclei that were Sox2+ and pStat3+ were identified by multiplying the thresholded DAPI, Sox2, and pStat3 images together as shown in Supplementary Figure S4. Finally, the x- and y-coordinates of cells that were manually added had to be within five pixels of a DAPI+ location to count toward the final tally of nuclei.

For nonnuclear antibodies (Iba1 and GFAP), cells were counted when DAPI nuclei were completely surrounded by the label. GFAP+ cells were manually counted because of the complex network of astrocyte labeling within the ONH.

For a subset of ONHs, nuclear densities calculated by the Matlab program were validated by comparing these semi-automated nuclear counts with manual counts performed by a second, independent observer (using Adobe Photoshop CS6 tools; Adobe Systems, San Jose, CA, USA). For this validation study, we focused on comparing anterior ONH nuclear densities done by both methods. An exception was made for Olig2, where nuclear densities in transition ONH were analyzed. There was excellent agreement ($P \geq 0.9$) between calculated nuclear densities provided by the two approaches for all primary antibodies (Supplementary Table S3).

Statistical Analysis

One-way ANOVA, followed by Dunnett’s multiple comparison test, was used to identify differences in IOP or nerve injury grades between controls and early injury or advanced injury groups.

Nuclear counts were transformed to nuclear densities by dividing the total number of nuclei by the evaluated ONH area. When more than one section per eye was processed, nuclear densities from all sections for a given ONH and region were averaged. Due to the low number of Ki67-labeled nuclei in a given section, proliferating cell nuclear density was calculated by summing the total nuclei divided by the summed area. Where necessary, data were transformed to avoid violating the assumptions of ANOVA.26-31 (However, the raw mean and standard error nuclear densities are reported in Table 2.) One-way ANOVA followed by Dunnett’s multiple comparison test was used to identify differences between controls and either early injury or advanced injury groups. Nerves included in the ONH regional analysis (comparison between anterior and transition ONH) needed to be long enough to have a transition
ONH Glial Proliferation and Jak-Stat Activation

Table 1. IOP History and Optic Nerve Grade by Injury Group

<table>
<thead>
<tr>
<th>Groups</th>
<th>Mean ± SD</th>
<th>Peak IOP</th>
<th>ON Grade</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td>22 ± 2</td>
<td>27 ± 3</td>
<td>1.0 ± 0.0</td>
<td>24</td>
</tr>
<tr>
<td>Early injury</td>
<td>23 ± 5</td>
<td>38 ± 10*</td>
<td>1.8 ± 0.9*</td>
<td>21</td>
</tr>
<tr>
<td>Advanced injury</td>
<td>30 ± 6*</td>
<td>55 ± 7*</td>
<td>4.8 ± 0.4*</td>
<td>16</td>
</tr>
</tbody>
</table>

Values are the mean ± standard deviation of the mean.
* Significantly different from respective controls (P < 0.05).

ONH region, and each nerve needed to have at least two sections processed and analyzed. Only a subset of samples met these criteria, and they are presented in Supplementary Table S4. Paired 2-way ANOVA, followed by Sidak’s multiple comparisons test, was used to identify differences by ONH region among groups. All statistical analyses were performed using statistical software (GraphPad Prism, version 6.0; GraphPad Software, Inc., La Jolla, CA, USA).

RESULTS

Elevated IOP and Optic Nerve Injury in Experimental Glaucoma Eyes

IOP parameters (mean IOP and peak IOP) and optic nerve injury grades for control, early injury, and advanced injury groups are summarized in Table 1 and Supplementary Figure S5. Mean IOP in advanced injury (P = 0.0001) and peak IOP in both early injury (P < 0.0001) and advanced injury (P < 0.0001) groups for the 5 weeks following hypertonic saline injection were significantly higher than controls, and duration of IOP elevation in the early injury group was less than in the advanced group. Similarly, nerve injury, as determined by optic nerve injury grade, was significantly greater than controls for both glaucoma model groups (P < 0.0001 for both). Additionally, more nerve injury was seen in advanced injury than in early injury (P < 0.0001).

In our previous microarray examination of ONH gene expression, we observed two dominant responses in ONH with early injury (less than 15% optic nerve degeneration), the upregulation of genes associated with cell proliferation and those associated with Jak-Stat signaling pathway.18,19 We will first present evidence of cell proliferation in the glaucoma model ONH. Then we will use cell specific markers to quantify total ONH nuclei. Glaucoma model ONHs with advanced injury had a twofold increase in nuclear densities in both the anterior (P < 0.0001) and transition (P < 0.0001) ONH relative to the control group (Fig. 2). Supplementary Figure S6 further illustrates increased cellularity in ONHs with advanced injury. There were no significant differences in DAPI densities between anterior and transition regions within groups (Supplementary Table 4). Regional comparisons presented in this and the following Results paragraphs are based on analysis of data presented in Supplementary Table 4.

Increased ONH Cellularity With Advanced Glaucomatous Injury

The nuclear counterstain DAPI was used to identify and quantify total ONH nuclei. Glaucoma model ONHs with advanced injury had a twofold increase in nuclear densities in both the anterior (P < 0.0001) and transition (P < 0.0001) ONH relative to the control group (Fig. 2). Supplementary Figure S6 further illustrates increased cellularity in ONHs with advanced injury. There were no significant differences in DAPI densities between anterior and transition regions within groups (Supplementary Table 4). Regional comparisons presented in this and the following Results paragraphs are based on analysis of data presented in Supplementary Table 4.
increased DAPI+ nuclear densities in both the anterior ONH ($N_{\text{Anterior}} = 14; N_{\text{Transition}} = 10$) and advanced injury ($N_{\text{Anterior}} = 9; N_{\text{Transition}} = 10$) ONHs. There was a significant increase (red asterisks) in mitotic nuclei in the anterior ONH of the early injury ($P = 0.0006$) and advanced injury ($P = 0.001$) groups when compared to controls (Table 2). There was no significant difference between anterior and transition ONH densities of mitotic cells within each group (Supplementary Table S4).

**Cell Proliferation in Glaucoma Model ONH**

To determine if the increased cellularity was, at least in part, due to cell proliferation, we immunostained ONH sections for the mitotic marker Ki67 (Fig. 3). Glaucoma ONHs with early injury ($P = 0.0006$) and advanced injury ($P = 0.001$) had significantly more proliferating nuclei than controls (Fig. 3; Table 2), with the highest values in ONHs with early injury. Note that the $y$-values shown in Figure 3 are a tenth of values plotted in other result figures, further indicating that a small proportion of nuclei are proliferating. Within groups, there were no significant differences between anterior and transition Ki67+ nuclear densities (Supplementary Tables S4).

**Astrocytic Proliferation in Glaucoma Model ONH**

Next, we determined which ONH cells were proliferating in glaucomatous injury. Because astrocytes are the most common cells of the ONH, we first quantified astrocytes using three specific markers, GFAP, Sox2, and Pax2. GFAP is the most commonly used astrocyte marker. However, GFAP is less than satisfactory for quantitative studies in the ONH because it labels the cytoskeleton (rather than nuclei) and because of the complex intertwining of astrocyte processes in the ONH (see Supplementary Fig. S3).

Because of this, two additional nuclear markers, Sox2 and Pax2, which produced a more discrete nuclear label, were used. Sox2 is associated with the maintenance of neural stem cells in adult neurogenic areas, which in the anterior ONH could only be astrocytes. Recently, Sox2 mRNA was identified as highly specific to astrocytes in the central nervous system. Sox2 counts agreed best with our counts of GFAP-labeled cells in the anterior region of early injury ONH ($1875 \pm 376$ and $4260 \pm 469$ cells/mm$^2$, respectively, $N > 8$). Furthermore, we found that between 81% (anterior ONH) and 93% (transition ONH) of Sox2+ nuclei were completely surrounded by GFAP-positive processes. Also, as observed in the mouse ONH, we found Sox2 labeled about 15% more nuclei than Pax2 in the anterior ONH (see Supplementary Fig. S3). Therefore, we used Sox2 to quantify ONH astrocytes.

Advanced injury ONH had more Sox2+ nuclei in the anterior ($P = 0.0001$) and transition ($P = 0.006$) regions than controls (Table 2). In regional comparisons within groups (Supplementary Table S4), there were approximately twice as many astrocytes (Sox2+) in the anterior compared to the transition region of all groups ($P$ values: controls = 0.05, early injury = 0.04, and advanced injury < 0.0001; Figs. 4A and 4B). Importantly, when colabeling of nuclei with Sox2 and Ki67 was examined in glaucoma model ONHs, we found that 80% (anterior) and 66% (transition) of mitotic cells labeled as astrocytes (Figs. 4C and 4D).

**Microglia/Macrophage Density and Proliferation Rates in Glaucoma Model ONH**

For ONH microglia, we used antibodies to Iba1, which also labels macrophages, such as tissue-resident macrophages. To avoid changes in cellular morphology (in response to injury) leading to an overcount of Iba1+ cells, we only counted DAPI+ nuclei that were contiguous with the surrounding Iba1+ label (Fig. 5). In general, we found that during active degeneration, the density of Iba1-labeled cells increased by more than fivefold in both ONH regions. Additionally, while Iba1-labeled cells were always most prevalent in the transition region, the proportion of mitotic Iba1 cells and the relative increase in Iba1 cell density was greatest in the anterior ONH.

More specifically, ONHs with advanced injury had more microglia/macrophages in the anterior ONH ($P = 0.01$) than controls. Additionally, the transition ONH with early injury ($P = 0.0001$) and advanced injury ($P = 0.0001$) had significantly more microglia/macrophages than their respective controls (Table 2). Also, when compared to ONHs with early injury, the advanced injury group had significantly more Iba1+ region (for the mitotic marker Ki67 (Fig. 3). Advanced injury group had significantly more proliferating nuclei than controls (Fig. 3; Table 2). There were no significant differences between anterior and transition ONH densities of mitotic cells within each group (Supplementary Table S4).
labeled cells in both ONH locations ($P = 0.0006$ for anterior ONH and $P < 0.001$ for transition ONH). In both regions, we found Iba1$^+$ cell densities to be positively correlated with optic nerve injury grade (anterior, $r^2 = 0.65$, $P < 0.0001$, and transition: $r^2 = 0.68$, $P < 0.0001$). For regional comparisons within groups (Supplementary Table S4), the glaucoma model ONHs had more Iba1$^+$ cells in the transition region than the anterior ONH ($P$ values: early injury $= 0.03$; advanced injury $= 0.02$).

When we examined colabeling of glaucoma model ONH with mitotic cell marker Ki67 and Iba1, we found approximately 14% (anterior) and 4% (transition) of Ki67$^+$ cells were colabeled as microglia/macrophage (Figs. 5C and 5D). Although there was a dramatic increase in Iba1$^+$ cells in the injured ONH, these cells were still the minority of proliferating cells in glaucoma model ONH.

Oligodendroglial Density in the Transition ONH and Lack of Proliferation in Glaucoma Model ONHs

The Olig2 antibody was used to identify oligodendroglial nuclei (Fig. 6). Olig2 encodes a basic-helix-loop-helix protein that regulates the development of oligodendrocytes in vertebrates.\textsuperscript{40-45} We found nearly all oligodendroglia in the transition ONH region, where densities did not differ significantly between controls and either experimental group ($P$ values: early injury $= 0.08$, and advanced injury $= 0.39$). We found fewer than five Olig2$^+$ nuclei in the anterior ONH in three samples. These tended to be closer to the transition ONH, likely indicating that these eyes were sectioned at a slightly oblique angle. More importantly, we found no Olig2 and Ki67 colabeling, indicating that there was no detectable proliferation of oligodendroglia in the ONH.
Proportional Contribution of Astrocytes, Microglia/Macrophage, and Oligodendroglia to ONH Cellularity in Glaucoma Model ONHs

Figure 7 summarizes the proportional contribution of each cell type to the total number of ONH nuclei by injury group. In general, the proportion of astrocytes (Sox2+ nuclei) decreased slightly in experimental glaucoma ONH, while the proportional contribution of microglia/macrophages (Iba1+ nuclei) increased. In the transition region, the proportion of oligodendroglia progressively decreased with increasing injury. Additionally, an increasing proportion of nuclei did not label with glial-specific antibodies. These would include non-glial cells, such as fibroblasts, endothelial cells, and pericytes that contribute to the total population of ONH nuclei, as well as any glial cells that fail to express the selected markers.

Jak-Stat Pathway Activation, as Indicated by pSTAT3 Labeling, Primarily Colocalizes With Astrocyte Markers While Colabeling With Microglia/Macrophages is Negligible

In our previous microarray studies, axonal injury in early chronic glaucoma was associated with an upregulation of genes involved with the Jak-Stat pathway. Activation of this pathway can occur when an Il6-type cytokine binds to transmembrane α and gp130 receptors, which then phosphorylates Jak2. Jak2 in turn phosphorylates Stat3 (pStat3). pStat3 homodimers translocate into the nucleus, activating transcription and regulating multiple downstream cell pathways, including proliferation. Here we utilized the pStat3 antibody to localize activation of the Jak-Stat pathway (Fig. 8). Stat3 phosphorylation at this site is associated with canonical Stat3 signaling and astrocyte reactivity.

Jak-Stat activation was significantly increased in the anterior ONH compared to the transition region. Furthermore, in the anterior ONH, Jak-Stat activation was primarily colocalized with astrocyte markers (Sox2), and only a small proportion of pStat3+ nuclei colabeled with microglia/macrophage markers (Iba1).

DISCUSSION

This study confirms two hypotheses we proposed based on our previous analysis of gene expression changes in glaucoma model ONHs. These are that there is evidence of (1) cell proliferation and (2) Il6-type cytokine signaling via the Jak-Stat signaling pathway in ONHs with early injury. Additionally, we demonstrate that, while both astrocytes and microglia/macroph-
phages proliferate in glaucoma model ONHs, the proliferation of astrocytes predominates.

Increases in cell density are not simply due to the loss of axons in these studies. In a previous study of axon counts versus injury grade in this model, we observed that only 15% of axons were injured in nerves with early injury.47 Even in nerves with advanced injury, approximately 40% of axons were morphologically normal while axonal debris was in the initial stages of clearance. Importantly, three-dimensional reconstructions of early injury ONH from our model demonstrate that the volume of the ONH increases dramatically. 20 This increase is highly correlated with injury grade and results in an approximate doubling of the volume in ONHs with early injury (grade ¼ 3) compared to controls. Note that the data presented in our current study are based on two-dimensional cell density measurements and, therefore, will actually underestimate the increased cellularity in the expanded volume of early glaucoma ONH.

Significant increases in the number of proliferating ONH cells, the majority of which were identified as astrocytes, were seen in the anterior region in both glaucoma model ONH injury groups. The nuclear Ki67 protein has been shown to be expressed for approximately 24 hours and during all phases of the cell division cycle, including in glial cells.48–52 Ki67 protein is degraded in late mitosis and early G1 by the ubiquitin-proteasome system.53 While the overall average percentage of cells that were proliferating at the time of tissue collection was only 2%, from the above it is reasonable to use this as an estimate of the daily rate of proliferation during the entire experimental period (35 days). This rate, applied to the density of DAPI+ nuclei in control ONH (calculated mean advanced injury DAPI density = mean control DAPI density x 1.0235) yields an approximate calculated final density of 13,000 to 14,000 nuclei/mm² and could account for much of the increase in cell density observed in ONHs with advanced injury (Table 2). These increases would also include proliferating microvascular cells, fibroblasts, or other cells that do not label with the cell-type markers that we utilized, as suggested by Figure 7. Another is the proliferation of NG2 (Cspg4+ ) glial cells, which are only present in the transition region of the rat 54 and have previously been reported to contribute to an increase in the number of oligodendrocytes in myelinated DBA/2J optic nerves with extensive axonal loss.55

While ischemia/reperfusion brain injury has been reported to induce astrocyte proliferation,56–57 in our microarray study quantifying ONH gene expression changes in nerves with pressures and injury similar to that of the current study, we found that expression of Hif1 and Epo (two hypoxia-related markers) were not significantly different from controls in either early or advanced injury. This, along with optical coherence tomography angiography evidence that retinal and ONH blood flow are not compromised until IOP is well above...
60 mm Hg suggests that the astrocyte proliferation observed here is unlikely to be simply a result of ischemia because peak IOPs do not exceed 60 mm Hg during the experimental time period (Supplementary Fig. 55).

As anticipated, we found that Iba1-labeled cells (microglia or macrophages) increased in density in injured ONH. Previously, we reported that these increases were correlated with mean IOP exposure, so the proportional relationship to nerve injury reported here was not surprising. However, it is important to note that proliferating Iba1-labeled cells constitute a minority of the mitotic cells in both the anterior and transition ONH regions. In general, in the current study, the Iba1 cell density did not significantly increase until axonal degeneration was advanced, indicating that microglia/macrophage densities are greatest when there is extensive axonal degeneration. Proliferation of these cells is a characteristic response to neural injury in the brain, retina, and optic nerve, and microglia/macrophage proliferative responses have been studied in other glaucoma models in addition to ours. Using the laser photocoagulation model, Ebnet et al. demonstrated activation of Iba1- and Ed1 (Cd68)-labeled cells in the retina. ONH, optic nerve, and optic tract, as evidenced by an increase in the labeled area that was correlated with the degree of axonal injury. Bosco et al. demonstrated that early gliosis in DBA/2J mouse optic disks, as detected by confocal scanning laser ophthalmoscopy of CX3CR1+/GFP-labeled cells (microglia or macrophage), was correlated with the degree of optic nerve axonal degeneration. Lastly, it is important to point out that the increase in cell density reported here cannot be attributed primarily to monocytes, since cells labeled with the dual microglial/monocyte marker Iba1 remained a minor component of the ONH, particularly in the anterior region.

While alterations in astrocyte morphology have been documented in glaucoma model ONHs with early injury, simultaneous increases in astrocyte density and proliferation in the ONH have not been carefully documented. We show here that astrocytes constitute the most abundant glial cell type in both the anterior and transition regions of the ONH. In our glaucoma model ONHs, during a time of active axon degeneration, astrocytes more than doubled in density in the anterior region. Additionally, astrocytes accounted for approximately 80% of mitotic glia in the anterior (unmyelinated) ONH and about 65% in the transition region.

When there is destruction of neural tissue, such as in spinal cord injuries or cortical stab wounds, up to 50% of affected astrocytes may divide within a few days and are thought to form a barrier between the lesion and surrounding tissue. In other types of neural injury, proliferation of microglia or oligodendroglia predominates whereas astrocyte proliferation is less, including in the ONH following optic nerve transection. The robust astrocytic proliferative response observed here by elevated IOP alone may be a unique aspect of early glaucomatous damage in the ONH. The predominance of these early responses in the anterior region, which is the site of the glial lamina and analogous to the primate lamina cribrosa, is consistent with the widely recognized observation that, in glaucoma, the lamina cribrosa is the primary site of injury.

The overall impact of astrocyte proliferation on axon integrity in this glaucoma model is likely twofold. First, while undergoing cell division, astrocytes change in morphology and their specific gene and protein expressions are altered, all of which may compromise their ability to provide functional support to axons passing through the ONH. In the ONH, as elsewhere in the nervous system, astrocytic functions include regulation of water and ion fluxes, support for action potential propagation, the provision of metabolic precursors via vascular interactions and glycan storage, the supply of neurotrophic factors and antioxidants, the provision of communication and diffusion via gap junctions, the removal of cellular debris, and the generation of extracellular matrix. Unmyelinated axons of the anterior ONH are particularly vulnerable to this decreased support due to their high metabolic demands. Second, cell proliferation itself is an energy-consuming process that can double astrocyte glucose uptake. Therefore, cell proliferation in the injured ONH is likely to place an additional metabolic stress on injured and remaining ONH axons.

In our microarray study, we identified upregulation of cell proliferation genes as well as genes associated with interleukin 6-type cytokines and the Jak-Stat signaling pathway. Here we demonstrate that early in glaucomatous injury, the transcription factor, Stat3, is activated by phosphorylation in the ONH and that this occurs primarily in astrocytes. This labelling is most dramatic in conjunction with significant Ki67 labeling in these cells in the anterior region of the ONH, where the greatest increase in astrocyte density occurs. This suggests that Stat3 phosphorylation may signal astrocyte proliferation in response to elevated IOP injury. A key role for this pathway in astrocyte proliferation has been described in the spinal cord and brain injury. Stat3 has been identified as necessary and sufficient for astrocyte differentiation and is a central regulator of astrocyte reactivity and proliferation. While alterations in astrocyte morphology have been documented in glaucoma model ONHs with early injury, simultaneous increases in astrocyte density and proliferation in the ONH have not been carefully documented. We show here that astrocytes constitute the most abundant glial cell type in both the anterior and transition regions of the ONH. In our glaucoma model ONHs, during a time of active axon degeneration, astrocytes more than doubled in density in the anterior region. Additionally, astrocytes accounted for approximately 80% of mitotic glia in the anterior (unmyelinated) ONH and about 65% in the transition region.

When there is destruction of neural tissue, such as in spinal cord injuries or cortical stab wounds, up to 50% of affected astrocytes may divide within a few days and are thought to form a barrier between the lesion and surrounding tissue. In other types of neural injury, proliferation of microglia or oligodendroglia predominates whereas astrocyte proliferation is less, including in the ONH following optic nerve transection. The robust astrocytic proliferative response observed here by elevated IOP alone may be a unique aspect of early glaucomatous damage in the ONH. The predominance of these early responses in the anterior region, which is the site of the glial lamina and analogous to the primate lamina cribrosa, is consistent with the widely recognized observation that, in glaucoma, the lamina cribrosa is the primary site of injury.

The overall impact of astrocyte proliferation on axon integrity in this glaucoma model is likely twofold. First, while undergoing cell division, astrocytes change in morphology and their specific gene and protein expressions are altered, all of which may compromise their ability to provide functional support to axons passing through the ONH. In the ONH, as elsewhere in the nervous system, astrocytic functions include regulation of water and ion fluxes, support for action potential propagation, the provision of metabolic precursors via vascular interactions and glycan storage, the supply of neurotrophic factors and antioxidants, the provision of communication and diffusion via gap junctions, the removal of cellular debris, and the generation of extracellular matrix. Unmyelinated axons of the anterior ONH are particularly vulnerable to this decreased support due to their high metabolic demands. Second, cell proliferation itself is an energy-consuming process that can double astrocyte glucose uptake. Therefore, cell proliferation in the injured ONH is likely to place an additional metabolic stress on injured and remaining ONH axons.

In our microarray study, we identified upregulation of cell proliferation genes as well as genes associated with interleukin 6-type cytokines and the Jak-Stat signaling pathway. Here we demonstrate that early in glaucomatous injury, the transcription factor, Stat3, is activated by phosphorylation in the ONH and that this occurs primarily in astrocytes. This labelling is most dramatic in conjunction with significant Ki67 labeling in these cells in the anterior region of the ONH, where the greatest increase in astrocyte density occurs. This suggests that Stat3 phosphorylation may signal astrocyte proliferation in response to elevated IOP injury. A key role for this pathway in astrocyte proliferation has been described in the spinal cord and brain injury. Stat3 has been identified as necessary and sufficient for astrocyte differentiation and is a central regulator of astrocyte reactivity and proliferation.
**Acknowledgments**

Supported by NIH/NEI Grants R01EY010145-17S1 (DCL), R01EY-010145 (JCM), R01EY016866 (ECJ); and P30 EY010572 (OHSU), and by unrestricted departmental funding from Research to Prevent Blindness (New York, NY, USA).

Disclosure: D.C. Lozano, None; T.E. Choe, None; W.O. Cepurna, None; J.C. Morrison, None; E.C. Johnson, None

**References**


77. Quigley HA, Hohman RM, Addicks EM, Massof RW, Green WR. Morphologic changes in the lamina cribrosa correlated
87. Ritchie JM. The oxygen consumption of mammalian non-myelinated nerve fibres. J Physiol. 1966;180:120P.